Prostate Cancer Treatments

Mark Emberton holds the post of Professor in Interventional Oncology at University College London and is Associate Professor at Middlesex University, London. At UCLH he is Pathway Director for Urological Cancer for UCL Partners. He is also Honorary Clinical Director of the Clinical Effectiveness Unit at the Royal College of Surgeons of England. His clinical and research interests are focused mainly on diseases of the prostate gland, both benign and malignant. In prostate cancer much of his activity is at present focused on evaluating minimally invasive therapies for localised prostate cancer. This work encompasses the fields of precise characterisation of disease as well as targeting therapies. A current interest includes the non invasive evaluation of men at risk of having prostate cancer.

Professor Emberton is also interested in the methodological aspects of clinical research, particularly on the use of alternatives to the randomised control trial in surgery. He is involved in guideline production and appraisal and is interested in the formulation of evidence based management policies. He is an active researcher, lectures widely and has published over 100 peer reviewed publications as well as numerous books and chapters. He is a founding Partner of London Urology Associates, and is a Trustee of Prostate Action.

Special Interests

Prostate cancers, benign prostate hyperplasia, Prostatitis, High Intensity Focused Ultrasound (HIFU), electroporation

-

Special Interests

-

Paul is a consultant urological surgeon at both Bart's Health and University College Hospital London. Paul was fellowship trained in robotic prostate cancer surgery in Melbourne Australia under the tutorage of Professor Tony Costello ' one of the world's leading robotic prostate cancer surgeons. Paul performs on average around 100 robotic prostate cancer operations each year. Paul's particular clinical focus includes nerve-sparing robotic radical prostatectomy, radical prostatectomy for high-risk prostate cancer and salvage-robotic radical prostatectomy.

Special Interests

Nerve-sparing robotic radical prostatectomy, radical prostatectomy for high-risk prostate cancer and salvage-robotic radical prostatectomy

Ben Challacombe was appointed consultant urological surgeon to Guy’s and St Thomas’ Hospitals in 2010 following his dedicated da Vinci robotic fellowship in Melbourne, Australia. He is able to offer patients complex surgery of the prostate, bladder and kidney, with a particular focus on laparoscopic and robotic procedures. His specialist training included periods at Guy’s and St Thomas’, The Royal Melbourne and The Royal Marsden Hospitals. He is involved in academic research into prostatic disease having written over 70 peer-reviewed publications and 20 book chapters on this subject. Ben won the Rowan Nicks UK and Ireland Scholarship from the Royal Australasian College of Surgeons in 2009.

Special Interests

Robotic Prostatectomy, Kidney Cancer, Laparoscopic Nephrectomy, Robotic assisted Partial Nephrectomy, Holmium Laser Enucleation of the Prostate (HoLEP)

Christopher Eden attended Guy’s Hospital and King’s College Hospital Medical Schools, achieving an MBBS in 1985 from the University of London after winning Surgery and Paediatric Prizes. He became a Fellow of the Royal College of Surgeons in 1995 and achieved a Master of Surgery degree from the University of London in 1997. He is currently Professor of Urology at the University of Surrey, Consultant Urological Surgeon at The Royal Surrey County Hospital, Guildford, UK and Co-Director of Santis.

Special Interests

Surgery for high-risk prostate cancer

By 1988, Maurice Lau had graduated from the Universities of St Andrews and Manchester with a BSc in medical sciences and the MBChB. He trained in the North West and became a consultant urological surgeon, fully accredited by the Royal College of Surgeons. His initial appointment, with an interest in uro-oncology, was to the Wrightington Hospital, Wigan and Leigh NHS Foundation Trust, in 2000. Mr Lau was then appointed to Salford Royal Hospital and The Christie in 2006, working solely in oncology. One of Mr Lau’s areas of interest is prostate cancer, undertaking open radical retropubic prostatectomies and robot assisted laparoscopic prostatectomies, as well as laparoscopic nephrectomies. He is also a member of the Northwest Robotic group. He has established transperineal ultrasound guided template biopsy of the prostate which can improve the diagnostic rate for prostate cancer, particularly in difficult cases where transrectal biopsies have been negative for cancer but the prostate specific antigen (PSA) remains elevated. In addition, Maurice Lau has helped shape penile surgery services in the North West.

Special Interests

Prostate

Vijay Ramani has been appointed as a consultant urological surgeon at University Hospital South Manchester and The Christie, Manchester since 1999. His specialist interest is in prostate, bladder, renal, testis and complex pelvic and retroperitoneal cancers. Mr Ramani is a member of the Northwest Robotic Group and has also been responsible for the introduction and advancement of robotic surgery at The Christie and regularly undertakes robot assisted laparoscopic prostatectomy on patients with localised adenocarcinoma prostate. His other specialist operations including radical cystectomy and neobladder reconstruction, partial nephrectomy for small renal tumours, radical nephrectomy and complex inferior vena cava surgery. Mr Ramani also undertakes surgery for testis cancer including primary orchidectomy and retroperitoneal lymph node dissection. He is currently Clinical Lead for Urology at University Hospital South Manchester and a Lecturer of the European School of Urology. Mr Ramani has given lectures regionally, nationally and internationally on urological cancers and regularly recruits patients to trials through the specialist MDT set up. He also consults on the prostate and issues surrounding men’s health.

Special Interests

Urological oncology: Diagnostic work -up and Treatment;
Prostate: Robot Assisted Laparocopic Radical Prostatectomy (Robotic Radical Prostatectomy) for Prostate Cancer, Prostate Disease